CLEVELAND and INDIANAPOLIS, February 12, 2018 – Allinaire Therapeutics has been awarded a Phase I Small Business Technology Transfer grant from the National Heart, Lung and Blood Institute. Allinaire’s aim is to support the advancement of new drug therapies for pulmonary diseases.

Allinaire was formed by BioMotiv, Indiana University Research & Technology Corp (IURTC), BioCrossroads, and Innovate Indiana. The company has previously received several grant awards from the Department of Defense and National Institutes of Health.


Read full press release here.